Content area
Full text
About the Authors:
Anna M. Lilja
* E-mail: [email protected] (AL); [email protected] (NHG)
Affiliations Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden, Drug Design and Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America
Yu Luo
Affiliation: Department of Neurological Surgery, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America
Qian-sheng Yu
Affiliation: Drug Design and Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America
Jennie Röjdner
Affiliations Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden, Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
Yazhou Li
Affiliation: Drug Design and Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America
Ann M. Marini
Affiliation: Department of Neurology and Neuroscience Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America
Amelia Marutle
Affiliation: Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
Agneta Nordberg
Affiliations Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden, Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
Nigel H. Greig
* E-mail: [email protected] (AL); [email protected] (NHG)
Affiliation: Drug Design and Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America
Introduction
Alzheimer’s disease (AD), a progressive neurodegenerative condition resulting in memory loss and neuropsychiatric disturbances, is the most common form of dementia and afflicts in excess of 26 million people worldwide [1]. Its economic burden and impact on the quality of life of both patients and their caregivers are overwhelming and continue to escalate [2], [3]. Existing therapeutic options remain limited, and numerous recent AD experimental drugs have failed to demonstrate clinical efficacy [4]. The concerning 66% rise in the proportion of AD related deaths that occurred between 2000 and 2008, in the face of declines in deaths from the leading illnesses...